ShEEP Request for CytoViva 3D Darkfield Hyperspectral Microscope

ShEEP 请求 CytoViva 3D 暗场高光谱显微镜

• 批准号: 9906462
• 负责人: Rajagopal Ramesh
• 金额: --
• 依托单位: OKLAHOMA CITY VA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-01 至 2020-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9906462
• 关键词: 3-Dimensional; Acute; Alzheimer' s Disease; Antibodies; Area; Arthritis; Award; Bacteria; Bacterial Infections; Binding; Biological; Cancer Biology; Cancer Center; Cells; Chronic Disease; Cities; Communities; Computer software; Consumption; Core Facility; Diagnosis; Disease; Drug Delivery Systems; Drug Prescriptions; Equipment; Family member; Funding; Future; Grant; Health Sciences; Healthcare Systems; Hepatitis; Image; Imagery; In Vitro; Inflammatory Bowel Diseases; Institutes; Institution; Intravenous; K-Series Research Career Programs; Label; Lead; Leadership; Legal patent; Maintenance; Malignant Neoplasms; Measurement; Mediating; Metals; Microscope; Military Personnel; Monitor; Noise; Oklahoma; Optics; Oral; Organelles; Organism; Pain; Pancreatitis; Patients; Peer Review; Pharmaceutical Preparations; Phase I Clinical Trials; Post-Traumatic Stress Disorders; Process; Protocols documentation; Quality of life; Quantum Dots; Reproduction spores; Research; Research Activity; Research Infrastructure; Research Personnel; Resources; Role; Route; Sampling; Scientist; Sheep; Ships; Signal Transduction; Small Interfering RNA; Surveys; Symptoms; System; Technology; Therapeutic; Time; Tissues; Training; Treatment Failure; Treatment outcome; United States National Institutes of Health; Universities; Veterans; Virus; Virus Diseases; Walking; Woman; animal imaging; cancer clinical trial; cancer therapy; career; clinical translation; design; drug development; drug efficacy; experience; experimental study; flexibility; human disease; improved; ineffective therapies; instrument; instrumentation; intraperitoneal; men; nanomedicine; nanoparticle; off-patent; particle; pathogen; plasmid DNA; receptor; software systems; tool; trafficking

One of the challenges in areas of drug development and drug delivery for treating various human diseases is the lack of understanding of the inherent cellular barriers that restrict the drug efficacy. Another challenge encountered by researchers conducting intracellular trafficking of molecules and their localization in cellular organelles is in the use of fluorescent labels that distort the study results with negative influence of these labels on samples. Further, lack of availability of adequate instrumentation restricts investigators from conducting cutting-edge research at their own institute. As a result they have to ship their materials to institutions/universities which are time-consuming, expensive, and do not give the investigator to know the results quickly. Therefore, continuous expansion of research infrastructure by acquiring appropriate equipment’s will enhance research activities among research investigator and lead to new discoveries. To override some of these limitations, we are requesting funds to purchase the CytoViva 3D Enhanced Darkfield Hyperspectral Microscope for enhancing the research conducted by investigators at the Oklahoma City VA Health Care System. This system offers high signal-to-noise 3D enhanced darkfield optical hyperspectral imaging specifically designed for imaging of label free particles/molecules in label-free or fluorescently labeled live cells and ex-vivo tissue matrices. The unique patented technology of the microscope allows the visualization and monitoring of particles, drugs, biologics, and cells in solution and in translucent matrices (cells, tissues, organisms). Thus, studies investigating binding of material (drug, nanoparticle, cell- particle interaction, antibody binding to cell), receptor-mediated binding and entry into cells (nanoparticles, quantum-dots, virus, bacteria, metals, antibodies) and intracellular localization and trafficking (siRNA, plasmid DNA, nanoparticles, virus, bacteria, spores) via various intracellular organelles can be determined in vitro and in ex-vivo tissue explants with label-free imaging and capture images. The system with the requisite computer software system provides quantitative spectral analysis of biological and non-biological materials imaged. The protocols can be automated giving the user to ‘walk-away’ from the instrument, and perform other experiments. Most importantly, neither the Oklahoma City VA Health Care System nor the affiliated University of Oklahoma Health Sciences Center (OUHSC) has such an instrument that enables high precision analysis of label-free materials in cells or ex-vivo tissues. Therefore, this is a truly unique and valuable resource justifying it purchase as a resource for investigators to conduct existing and new areas of research at the Oklahoma City VA Health Care System. Availability of this equipment will enhance ongoing studies and establish new areas of research benefitting the men and women serving the military and veterans. The equipment will be used by six-major users and a number of future VA users who have six VA Merit grants funded, three senior career scientist awards, and one career development award funded.

治疗各种人类疾病的药物开发和药物输送领域的挑战之一